These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 6446874)

  • 1. The relationships of aging changes in the basal ganglia to manifestations of Huntington's chorea.
    Finch CE
    Ann Neurol; 1980 May; 7(5):406-11. PubMed ID: 6446874
    [No Abstract]   [Full Text] [Related]  

  • 2. The brain in Huntington's chorea.
    Bird ED
    Psychol Med; 1978 Aug; 8(3):357-60. PubMed ID: 151869
    [No Abstract]   [Full Text] [Related]  

  • 3. Beta-adrenergic receptor subtypes in the basal ganglia of patients with Huntington's chorea and Parkinson's disease.
    Waeber C; Rigo M; Chinaglia G; Probst A; Palacios JM
    Synapse; 1991 Aug; 8(4):270-80. PubMed ID: 1656540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of phosphodiesterase 10A, dopamine receptors D1 and D2 and dopamine transporter ligand binding in the striatum of the R6/2 and BACHD mouse models of Huntington's disease.
    Miller S; Hill Della Puppa G; Reidling J; Marcora E; Thompson LM; Treanor J
    J Huntingtons Dis; 2014; 3(4):333-41. PubMed ID: 25575954
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Methamphetamine increases basal ganglia iron to levels observed in aging.
    Melega WP; Laćan G; Harvey DC; Way BM
    Neuroreport; 2007 Oct; 18(16):1741-5. PubMed ID: 17921879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
    Perry TL; Hansen S; Kloster M
    N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
    [No Abstract]   [Full Text] [Related]  

  • 7. Regulation of dopamine receptor and neuropeptide expression in the basal ganglia of monkeys treated with MPTP.
    Betarbet R; Greenamyre JT
    Exp Neurol; 2004 Oct; 189(2):393-403. PubMed ID: 15380489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease.
    Lastres-Becker I; Hansen HH; Berrendero F; De Miguel R; Pérez-Rosado A; Manzanares J; Ramos JA; Fernández-Ruiz J
    Synapse; 2002 Apr; 44(1):23-35. PubMed ID: 11842443
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distribution and release of GABA in the basal ganglia.
    Korf J; van der Heyden JA; Venema K; Postema F
    Adv Biochem Psychopharmacol; 1981; 30():105-17. PubMed ID: 7331934
    [No Abstract]   [Full Text] [Related]  

  • 10. Effect of MPTP-induced denervation on basal ganglia GABA(B) receptors: correlation with dopamine concentrations and dopamine transporter.
    Calon F; Lavertu N; Lemieux AM; Morissette M; Goulet M; Grondin R; Blanchet PJ; Bédard PJ; Di Paolo T
    Synapse; 2001 Jun; 40(3):225-34. PubMed ID: 11304760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Model of choreic movement in monkey--contribution for understanding the mechanism of chorea in Huntington's disease].
    Kanazawa I
    Jikken Dobutsu; 1990 Apr; 39(2):168-72. PubMed ID: 2141819
    [No Abstract]   [Full Text] [Related]  

  • 12. Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.
    Buck SH; Burks TF; Brown MR; Yamamura HI
    Brain Res; 1981 Mar; 209(2):464-9. PubMed ID: 6164436
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular distribution of ferric iron, ferritin, transferrin and divalent metal transporter 1 (DMT1) in substantia nigra and basal ganglia of normal and beta2-microglobulin deficient mouse brain.
    Moos T; Trinder D; Morgan EH
    Cell Mol Biol (Noisy-le-grand); 2000 May; 46(3):549-61. PubMed ID: 10872742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Toxic action of kainic acid as a model of Huntington chorea and epilepsy (review)].
    Levin SL; Sytinskiĭ IA
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1983; 83(5):754-63. PubMed ID: 6224382
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent developments in Parkinson's disease and Huntington's chorea.
    Barbeau A
    Int J Neurol; 1976; 11(1):17-27. PubMed ID: 138661
    [No Abstract]   [Full Text] [Related]  

  • 16. Increased TRH content of the basal ganglia in Huntington's disease.
    Spindel ER; Wurtman RJ; Bird ED
    N Engl J Med; 1980 Nov; 303(21):1235-6. PubMed ID: 6448349
    [No Abstract]   [Full Text] [Related]  

  • 17. [Neurotransmitters in Huntington chorea (review)].
    Barkhatova VP; Larskiĭ EG
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1985; 85(3):444-50. PubMed ID: 2581405
    [No Abstract]   [Full Text] [Related]  

  • 18. Regional specificity of brain atrophy in Huntington's disease.
    Halliday GM; McRitchie DA; Macdonald V; Double KL; Trent RJ; McCusker E
    Exp Neurol; 1998 Dec; 154(2):663-72. PubMed ID: 9878201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Basal ganglia lesions and neurotransmitters].
    Yoshida M
    Nihon Rinsho; 1978; 36(1):58-64. PubMed ID: 24766
    [No Abstract]   [Full Text] [Related]  

  • 20. [Therapy of Huntington's chorea: a pharmacological and clinical approach to the organization of the basal ganglia].
    Roccatagliata G; Albano C
    Clin Ter; 1980 Aug; 94(3):249-56. PubMed ID: 6450021
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.